ADC Therapeutics SA(ADCT)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$1.03
- 52-Week Range
- $0.78 – $4.98
- YTD
- -70.74%
- IV Rank (30D)
- 87.23
- Straddle Price
- $2.60
- P/C Vol Ratio
- 0.64
- Market Cap
- $0.1B
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 7.78% |
| Volatility Risk Premium | +192.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +10.7% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | 63.3% |
| Book / Price | -153.7% |
| Gross Margin (TTM) | 90.7% |
| FCF Margin (TTM) | -144.7% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $3.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.65 |
| Bollinger Width / SMA20 | 5831.0% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: AMD, GEV, HCA, JNJ, LLY, LRCX, MRK, ROIV
Blended Fair Value
$3.88
Current Price
$1.05
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 32.9× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 29.0× · 7 peers |
| Peer P/B | n/a | 0% | median 11.4× · 7 peers |
| Peer P/S | $6.55 | 16% | median 10.0× · 8 peers |
| Market Anchor (SMA50) | $3.36 | 84% | stability 78% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNYS
- Market Cap
- $0.1B
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241,…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +17.66% | 6 |
| Feb | +3.35% | 6 |
| Mar | -12.12% | 6 |
| Apr | -4.29% | 6 |
| May | +9.85% | 6 |
| Jun | -13.57% | 6 |
| Jul | -5.75% | 5 |
| Aug | -3.66% | 5 |
| Sep | -5.45% | 5 |
| Oct | -3.34% | 5 |
| Nov | -11.04% | 5 |
| Dec | +8.71% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.53
SMA 50: $3.31
SMA 200: $3.76
Current: $1.05
EMA 12: $1.78
EMA 26: $2.48
MACD: -0.6980 | Signal: -0.1911
BEARISH
ADX (14): 36.53
TREND
+DI: 11.93
−DI: 55.09
Momentum Oscillators
RSI (14): 14.83
OVERSOLD
Stoch %K: 9.93
Stoch %D: 9.99
Williams %R: -90.76
Volume & Volatility
BB Upper: $4.66
BB Lower: $0.40
NEUTRAL
OBV: -12,251,276
Vol SMA 20: 2,944,030
Vol ROC: 124.95%
ATR: $0.26
True Range: $0.10
HV 20: 313.9%
HV 30: 258.0%
HV 60: 187.6%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:20.923000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
10 of 10 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-06 | After-Close | 39.38% | 6.16% | 0.16x | Within |
| 2024-11-07 | After-Close | 179.53% | 1.68% | 0.01x | Within |
| 2025-01-13 | After-Close | 359.01% | 1.74% | 0.00x | Within |
| 2025-03-27 | After-Close | 411.18% | 0.00% | 0.00x | Within |
| 2025-05-14 | Pre-Market | 77.95% | 40.68% | 0.52x | Within |
| 2025-08-12 | After-Close | 20.41% | 5.10% | 0.25x | Within |
| 2025-10-14 | After-Close | 37.71% | 3.65% | 0.10x | Within |
| 2026-01-08 | Pre-Market | 246.25% | 1.91% | 0.01x | Within |
| 2026-03-10 | After-Close | 58.76% | 2.40% | 0.04x | Within |
| 2026-05-04 | After-Close | 37.72% | 2.47% | 0.07x | Within |
Options Activity
- IV Rank (30D)
- 87.23
- IV Rank (7D)
- 100
- Avg IV
- 462.5%
- Straddle (30D)
- $2.60
- Straddle (7D)
- $2.48
- P/C Volume
- 0.64
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.85
- Correlation (SPY)
- 25.1%
- R²
- 0.06
- Ann. Volatility
- 90.9%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 132,849,944 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$1.47M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | MILLENNIUM MANAGEMENT LLC Custodian | $1.01M | 68.72% | 2026-03-31 |
| 2 | Point72 Asset Management, L.P. | $198.00K | 13.44% | 2026-03-31 |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $136.50K | 9.26% | 2026-03-31 |
| 4 | JANE STREET GROUP, LLC Custodian | $95.25K | 6.46% | 2026-03-31 |
| 5 | SIMPLEX TRADING, LLC Custodian | $31.12K | 2.11% | 2026-03-31 |
1 filers$2.62K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $2.62K | 100.00% | 2026-03-31 |
Insider Activity
Latest: 2026-06-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Timothy Coughlin | Director | Mixed | +32,400 | $3.08 | -$38.8K | EDGAR |
| 2026-06-03 | Robert Azelby | Director | Mixed | +32,400 | $3.08 | -$38.8K | EDGAR |
| 2026-06-03 | JEAN-PIERRE BIZZARI | Director | Mixed | +32,400 | $3.08 | -$38.8K | EDGAR |
| 2026-06-03 | Ron Squarer | Director | Mixed | +29,804 | $3.08 | -$46.8K | EDGAR |
| 2026-06-03 | Victor Sandor | Director | Mixed | +32,400 | $3.08 | -$38.8K | EDGAR |
| 2026-06-03 | Peter Hug | Director | Mixed | +42,844 | $3.08 | -$6.6K | EDGAR |
| 2026-06-03 | Viviane Monges | Director | Mixed | +42,404 | $3.08 | -$8.0K | EDGAR |
| 2026-04-02 | Redmile Group, LLC | 10%+ Owner | Sell (S) | −17,641,245 | $3.34 | -$58.91M | EDGAR |
| 2026-02-18 | Lisa Michelle Kallebo | Chief Accounting Officer | Mixed | +57,467 | $3.99 | $229.3K | EDGAR |
| 2026-02-18 | PETER J GRAHAM | Chief Legal Officer | Mixed | +261,506 | $3.99 | $1.04M | EDGAR |
| 2026-02-18 | Jose Carmona | Chief Financial Officer | Mixed | +245,720 | $3.99 | $980.4K | EDGAR |
| 2026-02-18 | AMEET MALLIK | Chief Executive Officer | Mixed | +796,769 | $3.99 | $3.18M | EDGAR |
| 2026-02-18 | Mohamed Zaki | Chief Medical Officer | Mixed | +260,597 | $3.99 | $1.04M | EDGAR |
| 2025-12-09 | Lisa Michelle Kallebo | Chief Accounting Officer | Tax (F) | −7,140 | $3.29 | -$23.5K | EDGAR |
| 2025-12-09 | PETER J GRAHAM | Chief Legal Officer | Tax (F) | −49,508 | $3.29 | -$162.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
17 insiders · @ $1.05
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jeremy Green | 10%+ Owner | 28,762,443 | $30.20M | $8.41M | 4 | 2024-12-13 |
| 2 | Redmile Group, LLC | 10%+ Owner | 25,735,799 | $27.02M | -$58.91M | 2 | 2026-04-02 |
| 3 | HANS PETER WILD | 10%+ Owner | 9,788,944 | $10.28M | $0 | 1 | 2025-05-19 |
| 4 | AMEET MALLIK | Chief Executive Officer | 2,115,870 | $2.22M | -$133.2K | 6 | 2026-02-18 |
| 5 | Jose Carmona | Chief Financial Officer | 760,256 | $798.3K | $0 | 4 | 2026-02-18 |
| 6 | Mohamed Zaki | Chief Medical Officer | 682,417 | $716.5K | $0 | 4 | 2026-02-18 |
| 7 | Thomas Pfisterer | Director | 625,755 | $657.0K | -$4.2K | 3 | 2025-05-19 |
| 8 | PETER J GRAHAM | Chief Legal Officer | 620,540 | $651.6K | $0 | 4 | 2026-02-18 |
| 9 | Peter Hug | Director | 263,344 | $276.5K | -$3.4K | 5 | 2026-06-03 |
| 10 | Viviane Monges | Director | 186,447 | $195.8K | -$4.2K | 5 | 2026-06-03 |
| 11 | JEAN-PIERRE BIZZARI | Director | 151,902 | $159.5K | -$20.2K | 5 | 2026-06-03 |
| 12 | Victor Sandor | Director | 140,686 | $147.7K | -$20.2K | 5 | 2026-06-03 |
| 13 | Ron Squarer | Director | 138,627 | $145.6K | -$20.2K | 5 | 2026-06-03 |
| 14 | Lisa Michelle Kallebo | Chief Accounting Officer | 128,224 | $134.6K | $0 | 4 | 2026-02-18 |
| 15 | Robert Azelby | Director | 112,805 | $118.4K | -$20.2K | 5 | 2026-06-03 |
| 16 | Timothy Coughlin | Director | 72,400 | $76.0K | $0 | 2 | 2026-06-03 |
| 17 | GOKUL V HEMMADY | VP & CFO | 19,553 | $20.5K | $0 | 1 | 2007-03-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | -0.6 |
| P/S Ratio | 1.7 |
| EV/EBITDA | -0.2 |
| TTM Revenue | $0.1B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-0.99 |
| ROE | 63.3% |
| Debt/Equity | -0.53 |